Internalization of Commercial Organization
The company successfully transitioned to an internal commercial team, which is expected to drive broader adoption of PEMGARDA, with promising early indicators for near-term breakeven and continued revenue growth.
Pipeline Expansion and Discovery Programs
The company expanded its pipeline to include discovery programs targeting new viral diseases such as RSV and measles, aiming to create best-in-class medicines beyond COVID-19.
Strong Financial Position and Cost Management
The company reported $11.3 million in net product revenue for Q1 2025 and a reduction in operating expenses by 15% quarter-over-quarter, with a strong cash position of $48 million and potential access to $30 million in non-dilutive funding.
Inclusion in Clinical Guidelines
PEMGARDA has been included in the NCCN Guidelines for B-cell lymphomas, indicating recognition from medical guidelines for its usage.